PEG-MGF (Pegylated Mechano Growth Factor)

What Is PEG-MGF?

PEG-MGF is mechano growth factor (MGF) with a polyethylene glycol (PEG) polymer attached, a modification known as pegylation. MGF itself is the IGF-1Ec splice variant of insulin-like growth factor 1, and its research form is a synthetic peptide based on that variant’s unique E domain.

A 2026 review of performance-enhancing peptides acting on the growth hormone-IGF-1 axis listed pegylated mechano growth factor among the IGF-1 analogs, alongside IGF-1 Long R3. The review described these agents as unregulated peptides marketed as “research compounds.”^[1]

Peer-reviewed data on PEG-MGF are limited. Beyond that review, no primary studies of PEG-MGF in cells, animals or humans were found in PubMed as of October 2026.

Chemical Structure and Molecular Identity

PEG-MGF combines an MGF peptide with a PEG chain, but no peer-reviewed source found defines its exact structure. PubChem has no compound record for it, so this page does not state a formula, molecular weight or CAS number.

Pegylation in general means covalently attaching a polyethylene glycol polymer to a peptide or protein. Because PEG polymers are made in different chain lengths and can be attached at different positions, the identity of any pegylated peptide depends on details such as PEG size, linkage chemistry and attachment site. None of these are standardized for PEG-MGF in the published literature reviewed here.

Relationship to MGF

The peptide portion is derived from mechano growth factor, which is covered on its own page. Studies of non-pegylated MGF peptides cannot be assumed to describe PEG-MGF, because pegylation can change how a peptide is distributed, cleared and recognized.

What the Published Literature Covers

The published literature on PEG-MGF consists of a passing mention in one 2026 narrative review; no experimental studies of the molecule itself were identified. That review focused on peptides used outside regulated medicine and on how clinicians can interpret symptoms in patients using them.^[1]

The review stratified growth hormone-axis peptides into evidence tiers, ranging from regulatory-grade randomized trial data to a complete absence of human studies. It highlighted uncertainty about product composition, dose and combination practices in unregulated supply chains, and uncertainty around claimed performance and body-recomposition benefits.^[1]

PubMed searches for this compound also return studies of other pegylated proteins, including pegylated recombinant IGF-1 and pegylated growth hormone. Those are different molecules with different structures, and their results are not evidence about PEG-MGF.

With no PubChem record or standardized structure, PEG-MGF identity depends on HPLC and mass spectrometry data reported on a certificate of analysis.

Regulatory and Research Status

PEG-MGF is not approved by the US Food and Drug Administration or any other regulator for human use. The 2026 review noted the absence of regulatory approval for physique- or performance-related uses of the peptides it covered, including PEG-MGF.^[1]

Mechano growth factors are named among prohibited growth factors on the World Anti-Doping Agency’s Prohibited List. Given the lack of published experimental data, PEG-MGF’s properties, stability and biological activity have not been characterized in peer-reviewed research. Claims that pegylation extends the persistence or activity of MGF have not been tested in any published study of this specific molecule.